As biosimilars begin to gain ground in the country, Janssen, maker of a number of brand-name biologic products that face current or oncoming biosimilar competition, has launched a program—the Biologics Savings Partnership—that it says will offer patients brand-name biologics at prices similar to those of biosimilar options.
Like the United States, Canada lags behind the European Union in terms of number of biosimilars approved and uptake of these products. However, Canada has been taking strides forward with developing its biosimilars landscape, and recently, the country’s regulator approved the first rituximab biosimilar (Truxima) to treat both cancer and rheumatoid arthritis. Furthermore, some Canadian health plans are beginning to transition patients from brand-name infliximab (Remicade) and etanercept (Enbrel) to biosimilar options.
As biosimilars begin to gain ground in the country, Janssen, maker of a number of brand-name biologic products that face current or oncoming biosimilar competition, has launched a program—the Biologics Savings Partnership—that it says will offer patients brand-name biologics at prices similar to those of biosimilar options.
According to Janssen’s website for the program, while biologics are among the fastest-growing segments in the Canadian pharmaceutical industry and were responsible for 27% of drug costs for private health plans in 2017, “biosimilars alone may not be the answer to drug plan sustainability.”
Janssen says that that, because patients may have to cycle through multiple biologics during their lifetimes due to treatment failure, and not all biologics have available biosimilars, branded products remain an important option.
Janssen’s website also includes a page that states that “not all brand-name biologics and biosimilars work in the same way.” While the webpage goes on to describe the fact that different classes of biologics have different mechanisms of action, it does not explain that reference products and their biosimilars share the same mechanism of action.
“The Biologics Savings Partnership” enables access to savings across a breadth of brand name biologics in different classes and with different targets,” says Janssen. “This provides broader access to a range of biologic treatment options, including newer biologics, without an additional cost burden.”
At its corporate website, Janssen has also issued a position that states that, while biosimilars may present an opportunity for short-term cost-savings, those savings “should not compromise patient and physician choice. Decisions that are driven by price alone can have negative consequences for patients who are well-managed on current treatments.”
A recent investigation by Canada’s Competition Bureau found that Janssen had supplied its brand-name infliximab at the cost of 1 cent, given free infliximab to “a large number of patients,” and negotiated exclusive contracts that barred biosimilars—or even other innovator biologics—from formularies. The bureau stopped short of saying that the drug maker had hindered biosimilar competition, however, and closed its investigation.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Pure-Play Biosimilar Company Reports 10-Fold Revenue Increase for First Half of 2024
August 22nd 2024Alvotech reported $236 million in revenue for the first 6 months of 2024, a 10-fold increase from the same period the year prior. The new figures come after the company received its first 2 FDA approvals in 2024.